Learned by Reading
In the ICWSM 2009 Weblog Corpus:
It is expected that this work may help scientists pursue pharmacological, genetic, and physiological approaches to develop potential therapeutic targets that could repair or prevent abnormal stem cell growth which can lead to cancer. read more
(Parse)
(S1 (S (NP (PRP It))
(VP (VBZ is)
(VP (VBN expected)
(SBAR (IN that)
(S (NP (DT this) (NN work))
(VP (MD may)
(VP (VB help)
(S (NP (NNS scientists))
(VP (VB pursue)
(NP (ADJP (JJ pharmacological) (, ,) (JJ genetic) (, ,) (CC and) (JJ physiological)) (NNS approaches))
(S (VP (TO to)
(VP (VB develop)
(NP (NP (JJ potential) (JJ therapeutic) (NNS targets))
(SBAR (WHNP (WDT that))
(S (VP (MD could)
(VP (VB repair) (CC or) (VB prevent)
(NP (JJ abnormal) (NN stem) (NN cell) (NN growth))))
(SBAR (WHNP (WDT which))
(S (VP (MD can)
(VP (VB lead)
(PP (TO to)
(NP (NN cancer)))
(. .)
(VP (VB read)
(NP (JJR more)))))))))))
In the ICWSM 2009 Weblog Corpus:
This work, directed by Laurent Groc and Francis Chaouloff, may lead to the identification of new therapeutic targets for psychiatric illnesses such as post – traumatic stress disorder and depression.
(Parse)
(S1 (S (NP (NP (DT This) (NN work)) (, ,)
(VP (VBN directed)
(PP (IN by)
(NP (NNP Laurent) (NNP Groc) (CC and) (NNP Francis) (NNP Chaouloff))))
(, ,))
(VP (MD may)
(VP (VB lead)
(PP (TO to)
(NP (NP (DT the) (NN identification))
(PP (IN of)
(NP (NP (JJ new) (JJ therapeutic) (NNS targets))
(PP (IN for)
(NP (NP (JJ psychiatric) (NNS illnesses))
(PP (JJ such) (IN as)
(NP (VB post) (: -)
(NP (JJ traumatic) (NN stress) (NN disorder)) (CC and)
(NP (NN depression)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The application of the CDH technology in client projects is now an important part of our revenue stream – during 2008 we have already secured contracts for development work on four therapeutic targets and anticipate concluding several more over the next few months.
(Parse)
(S1 (S (S (NP (NP (DT The) (NN application))
(PP (IN of)
(NP (DT the) (NNP CDH) (NN technology)))
(PP (IN in)
(NP (NN client) (NNS projects))))
(VP (AUX is) (ADVP (RB now))
(NP (NP (DT an) (JJ important) (NN part))
(PP (IN of)
(NP (PRP$ our) (NN revenue) (NN stream)))
(: -)
(S (PP (IN during)
(NP (CD 2008)))
(NP (PRP we))
(VP (VP (AUX have) (ADVP (RB already))
(VP (VBN secured)
(NP (NP (NNS contracts))
(PP (IN for)
(NP (NP (NN development) (NN work))
(PP (IN on)
(NP (CD four) (JJ therapeutic) (NNS targets)))))
(CC and)
(VP (VBP anticipate)
(S (VP (VBG concluding)
(NP (JJ several) (JJR more))
(PP (IN over)
(NP (DT the) (JJ next) (JJ few) (NNS months)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
These insights into the role of the ChEL domain may represent potential therapeutic targets in the treatment of congenital hypothyroidism.
(Parse)
(S1 (S (NP (NP (DT These) (NNS insights))
(PP (IN into)
(NP (NP (DT the) (NN role))
(PP (IN of)
(NP (DT the) (NNP ChEL) (NN domain)))
(VP (MD may)
(VP (VB represent)
(NP (JJ potential) (JJ therapeutic) (NNS targets))
(PP (IN in)
(NP (NP (DT the) (NN treatment))
(PP (IN of)
(NP (JJ congenital) (NN hypothyroidism))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
New bioinformatics approaches can augment current research and lead to new discoveries to understand the pathogenesis of diabetic neuropathy and to identify more effective molecular therapeutic targets.
(Parse)
(S1 (S (NP (JJ New) (JJ bioinformatics) (NNS approaches))
(VP (MD can)
(VP (VB augment)
(NP (JJ current) (NN research) (CC and) (NN lead))
(PP (TO to)
(NP (JJ new) (NNS discoveries)))
(S (VP (VP (TO to)
(VP (VB understand)
(NP (NP (DT the) (NN pathogenesis))
(PP (IN of)
(NP (NNP diabetic) (NN neuropathy)))
(CC and)
(VP (TO to)
(VP (VB identify)
(NP (ADJP (RBR more) (JJ effective)) (JJ molecular) (JJ therapeutic) (NNS targets)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The recent deorphanization of the FFA receptor family has drawn attention to these G – protein – coupled receptors as potential therapeutic targets for the treatment of metabolic diseases.
(Parse)
(S1 (S (NP (NP (DT The) (JJ recent) (NN deorphanization))
(PP (IN of)
(NP (DT the) (NNP FFA) (NN receptor) (NN family))))
(VP (AUX has)
(VP (VBN drawn)
(NP (NN attention))
(PP (TO to)
(NP (NP (DT these) (NNP G) (PRN (: -)
(NP (NN protein)) (: -)) (VBN coupled) (NNS receptors))
(PP (IN as)
(NP (NP (JJ potential) (JJ therapeutic) (NNS targets))
(PP (IN for)
(NP (NP (DT the) (NN treatment))
(PP (IN of)
(NP (JJ metabolic) (NNS diseases)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The metabolome is now considered by some to be the most predictive phenotype: consequently, the comprehensive and quantitative study of metabolites is a desirable tool for diagnosing disease, identifying new therapeutic targets and enabling appropriate treatments.
(Parse)
(S1 (S (S (NP (DT The) (NN metabolome))
(VP (AUX is) (ADVP (RB now))
(VP (VBN considered)
(PP (IN by)
(NP (DT some)))
(S (VP (TO to)
(VP (AUX be)
(NP (DT the)
(ADJP (RBS most) (JJ predictive)) (NN phenotype)))))
(: :)
(S (ADVP (RB consequently)) (, ,)
(NP (NP (DT the)
(ADJP (JJ comprehensive) (CC and) (JJ quantitative)) (NN study))
(PP (IN of)
(NP (NNS metabolites))))
(VP (AUX is)
(NP (NP (DT a) (JJ desirable) (NN tool))
(PP (IN for)
(S (VP (VP (VBG diagnosing)
(NP (NN disease)))
(, ,)
(VP (VBG identifying)
(NP (JJ new) (JJ therapeutic) (NNS targets)))
(CC and)
(VP (VBG enabling)
(NP (JJ appropriate) (NNS treatments)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
It is expected that this work may help scientists pursue pharmacological, genetic, and physiological approaches to develop potential therapeutic targets that could repair or prevent abnormal stem cell growth which can lead to cancer.
(Parse)
(S1 (S (NP (PRP It))
(VP (AUX is)
(VP (VBN expected)
(SBAR (IN that)
(S (NP (DT this) (NN work))
(VP (MD may)
(VP (VB help)
(S (NP (NNS scientists))
(VP (VB pursue)
(NP (ADJP (JJ pharmacological) (, ,) (JJ genetic) (, ,) (CC and) (JJ physiological)) (NNS approaches))
(S (VP (TO to)
(VP (VB develop)
(NP (NP (JJ potential) (JJ therapeutic) (NNS targets))
(SBAR (WHNP (WDT that))
(S (VP (MD could)
(VP (VB repair) (CC or) (VB prevent)
(NP (NP (JJ abnormal) (NN stem) (NN cell) (NN growth))
(SBAR (WHNP (WDT which))
(S (VP (MD can)
(VP (VB lead)
(PP (TO to)
(NP (NN cancer)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
This this website World Alzheimers Day 2008 Special Report discusses the significant progress which occurred in the field of Alzheimer clinical research in 2008, including a discussion regarding the latest promising therapeutics which address new therapeutic targets.
(Parse)
(S1 (S (NP (DT This))
(NP (DT this) (JJ website) (NNP World) (NNP Alzheimers) (NNP Day) (CD 2008) (JJ Special) (NN Report))
(VP (VBZ discusses)
(NP (NP (DT the) (JJ significant) (NN progress))
(SBAR (WHNP (WDT which))
(S (VP (VBD occurred)
(PP (IN in)
(NP (NP (DT the) (NN field))
(PP (IN of)
(NP (NNP Alzheimer) (JJ clinical) (NN research)))))
(PP (IN in)
(NP (CD 2008)))
(, ,)
(PP (VBG including)
(NP (NP (DT a) (NN discussion))
(VP (VBG regarding)
(NP (NP (DT the) (JJS latest) (JJ promising) (NNS therapeutics))
(SBAR (WHNP (WDT which))
(S (VP (VBP address)
(NP (JJ new) (JJ therapeutic) (NNS targets)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
In silico protein predictions suggest that the identified cancer – specific splice variants encode proteins with potentially altered functions, indicating that they may be involved in pathogenesis and hence represent novel therapeutic targets.
(Parse)
(S1 (S (S (PP (IN In)
(NP (NN silico)))
(NP (NN protein) (NNS predictions))
(VP (VBP suggest)
(SBAR (IN that)
(S (NP (DT the) (VBN identified) (NN cancer)))
(: -)
(S (NP (JJ specific) (NN splice) (NNS variants))
(VP (VBP encode)
(NP (NNS proteins))
(PP (IN with)
(NP (ADJP (RB potentially) (VBN altered)) (NNS functions)))
(, ,)
(S (VP (VBG indicating)
(SBAR (IN that)
(S (NP (PRP they))
(VP (MD may)
(VP (VP (AUX be)
(VP (VBN involved)
(PP (IN in)
(NP (NN pathogenesis)))))
(CC and)
(VP (ADVP (RB hence)) (VB represent)
(NP (JJ novel) (JJ therapeutic) (NNS targets)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Determining the microbial composition in patients and healthy controls may thus provide novel therapeutic targets.
(Parse)
(S1 (S (S (VP (VBG Determining)
(NP (DT the) (JJ microbial) (NN composition))
(PP (IN in)
(NP (NP (NNS patients)) (CC and)
(NP (JJ healthy) (NNS controls)))
(VP (MD may) (ADVP (RB thus))
(VP (VB provide)
(NP (JJ novel) (JJ therapeutic) (NNS targets))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Anti – apoptotic B – cell lymphoma – 2 (Bcl – 2) family members have therefore emerged as potential therapeutic targets due to their critical role in proliferating cancer cells.
(Parse)
(S1 (S (NP (NP (NNS Anti)) (: -)
(NP (JJ apoptotic) (NNP B)) (: -)
(NP (NN cell) (NN lymphoma)) (: -) (CD 2) (PRN (-LRB- -LRB-)
(NP (NNP Bcl)) (: -)
(NP (CD 2)) (-RRB- -RRB-))
(NP (NN family) (NNS members)))
(VP (AUX have) (ADVP (RB therefore))
(VP (VBN emerged)
(PP (IN as)
(NP (NP (JJ potential) (JJ therapeutic) (NNS targets))
(ADJP (JJ due)
(PP (TO to)
(NP (NP (PRP$ their) (JJ critical) (NN role))
(PP (IN in)
(NP (VBG proliferating) (NN cancer) (NNS cells))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Current treatment strategies for patients with coronary artery disease ignore the individual response to antiplatelet agent (s), and likewise fail to identify therapeutic targets for platelet reactivity necessary to evaluate the intensity of treatment.
(Parse)
(S1 (S (NP (NP (JJ Current) (NN treatment) (NNS strategies))
(PP (IN for)
(NP (NP (NNS patients))
(PP (IN with)
(NP (JJ coronary) (NN artery) (NN disease)))
(VP (VP (VBP ignore)
(NP (NP (DT the) (JJ individual) (NN response))
(PP (TO to)
(NP (NP (JJ antiplatelet) (NN agent)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)))
(, ,) (CC and)
(VP (ADVP (RB likewise)) (VBP fail)
(S (VP (TO to)
(VP (VB identify)
(NP (NP (JJ therapeutic) (NNS targets))
(PP (IN for)
(NP (NN platelet) (NN reactivity)))
(ADJP (JJ necessary)
(S (VP (TO to)
(VP (VB evaluate)
(NP (NP (DT the) (NN intensity))
(PP (IN of)
(NP (NN treatment)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Inward – rectifier K + (Kir) channels play many important biological roles and are emerging as important therapeutic targets.
(Parse)
(S1 (S (NP (NN Inward) (: -) (NNP rectifier) (NNP K) (NNP +) (-LRB- -LRB-) (NNP Kir) (-RRB- -RRB-) (NNS channels))
(VP (VP (VBP play)
(NP (JJ many) (JJ important) (JJ biological) (NNS roles)))
(CC and)
(VP (AUX are)
(VP (VBG emerging)
(PP (IN as)
(NP (JJ important) (JJ therapeutic) (NNS targets)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
These intellectual property rights are central to Domainex’s proprietary position on CDH and its application to the cloning and expression of challenging therapeutic targets.
(Parse)
(S1 (S (NP (DT These) (JJ intellectual) (NN property) (NNS rights))
(VP (VBP are)
(ADJP (JJ central)
(PP (TO to)
(NP (NP (NP (NNP Domainex) (POS 's)) (JJ proprietary) (NN position))
(PP (IN on)
(NP (NP (NNP CDH) (CC and) (PRP$ its) (NN application))
(PP (TO to)
(NP (NP (DT the) (NN cloning) (CC and) (NN expression))
(PP (IN of)
(NP (JJ challenging) (JJ therapeutic) (NNS targets)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Many affected genes are known to be involved in sarcomagenesis; others are novel, including mediators of adipocyte differentiation, and may include valuable therapeutic targets.
(Parse)
(S1 (S (S (NP (JJ Many) (JJ affected) (NNS genes))
(VP (AUX are)
(VP (VBN known)
(S (VP (TO to)
(VP (AUX be)
(VP (VBN involved)
(PP (IN in)
(NP (NN sarcomagenesis))))
(: ;)
(S (NP (NNS others))
(VP (VP (AUX are)
(ADJP (JJ novel)) (, ,)
(PP (VBG including)
(NP (NP (NNS mediators))
(PP (IN of)
(NP (JJ adipocyte) (NN differentiation)))
(, ,) (CC and)
(VP (MD may)
(VP (VB include)
(NP (JJ valuable) (JJ therapeutic) (NNS targets)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
NAD (P) H oxidases and their products are potential therapeutic targets for regulating angiogenesis in vivo.
(Parse)
(S1 (S (NP (NP (NNP NAD) (PRN (-LRB- -LRB-) (NNP P) (-RRB- -RRB-)) (NNP H) (NNS oxidases)) (CC and)
(NP (PRP$ their) (NNS products)))
(VP (AUX are)
(NP (NP (JJ potential) (JJ therapeutic) (NNS targets))
(PP (IN for)
(S (VP (VBG regulating)
(NP (NN angiogenesis))
(PP (IN in)
(NP (NN vivo)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
G protein – coupled receptors (GPCRs) are the largest family of signaling proteins and the most common therapeutic targets.
(Parse)
(S1 (FRAG (NP (NNP G) (NN protein)) (: -)
(S (NP (NP (VBN coupled) (NNS receptors)) (PRN (-LRB- -LRB-)
(NP (NNS GPCRs)) (-RRB- -RRB-)))
(VP (AUX are)
(NP (NP (DT the) (JJS largest) (NN family))
(PP (IN of)
(NP (NP (VBG signaling) (NNS proteins)) (CC and)
(NP (DT the)
(ADJP (RBS most) (JJ common)) (JJ therapeutic) (NNS targets))))
(. .)))
In Wikipedia:
“Expert Opinion on Therapeutic Targets”’ is currently in its 13th year of publication, has an Impact Factor of 3.333, and is available online or is published in paper format 12 times a year.
(Parse)
(S1 (S ('' '')
(NP (NP (JJ Expert) (NN Opinion))
(PP (IN on)
(NP (NP (JJ Therapeutic) (NNS Targets)) ('' '') ('' '))))
(VP (VP (AUX is) (ADVP (RB currently))
(PP (IN in)
(NP (NP (PRP$ its) (JJ 13th) (NN year))
(PP (IN of)
(NP (NN publication)))))
(, ,)
(VP (AUX has)
(NP (NP (DT an) (NNP Impact) (NN Factor))
(PP (IN of)
(NP (CD 3.333)))))
(, ,) (CC and)
(VP (AUX is)
(NP (JJ available) (NN online))))
(CC or)
(VP (AUX is)
(VP (VBN published)
(PP (IN in)
(NP (NN paper) (NN format)))
(NP (NP (CD 12) (NNS times))
(NP (DT a) (NN year)))
(. .)))
And 185 more sentences.